Investigating how a specific RNA modification affects a type of cancer caused by arsenic exposure
Evaluating METTL1-mediated m7G tRNA methylation as a novel dependency in alveolar rhadomyosarcoma
['FUNDING_OTHER'] · DANA-FARBER CANCER INST · NIH-11232020
This study is looking at how a specific change in RNA might affect the growth of a type of cancer called alveolar rhabdomyosarcoma, which is linked to arsenic exposure, and it aims to find new ways to treat this cancer that could help patients in the future.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11232020 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of a specific RNA modification, known as m6A methylation, in the development of alveolar rhabdomyosarcoma, a type of cancer linked to arsenic exposure. The study aims to explore how the enzyme ALKBH1 influences this modification and its impact on gene expression related to tumor growth. By examining the mechanisms behind arsenic-induced skin cancer, the research seeks to identify new therapeutic targets that could lead to more effective cancer treatments. Patients may benefit from insights that could lead to targeted therapies based on these findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with alveolar rhabdomyosarcoma or those with a history of arsenic exposure.
Not a fit: Patients with cancers unrelated to arsenic exposure or those not diagnosed with alveolar rhabdomyosarcoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients suffering from arsenic-induced cancers.
How similar studies have performed: While the specific focus on ALKBH1 and m6A methylation in this context is novel, previous research has shown promise in targeting RNA modifications for cancer therapy.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WILKINSON, EMMA ANNE — DANA-FARBER CANCER INST
- Study coordinator: WILKINSON, EMMA ANNE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy, arsenic induced cancer, cancer biomarkers, cancer markers, cancer therapy